Seungshin Yu is Executive Director of Strategic Business Development Division at ViroMed Co., Ltd, headquartered in Seoul, Korea. She received her BS, MS, and PhD in Microbiology from Seoul National University, and was a postdoctoral scholar at the Whitehead Institute for Biomedical Research, MIT. She began her career as a researcher at ViroMedica Pacific in 1997, a biotechnology spin-off from Seoul National University in 1996 and the matrix of ViroMed today. Her involvement in gene delivery vector development led to the births of retroviral vector and naked plasmid DNA vector platform. The delivery vectors became the backbone of the company’s many key clinical projects, such as chronic granulomatous disease gene therapy VM106, ischemic and degenerative cardiac and neurological disease gene therapy VM202, and anti-cancer gene therapy vaccine VM206, all in clinical phases underway. Retroviral vector system was out-licensed to Takara Shuzo in Japan (now Takara Bio), and recently, chimeric antigen receptor T-cell technology based anti-cancer gene therapy technology was out-licensed to Bluebird Bio in the US. After serving as the first R&D Center director of the company, she is now responsible for IP, research planning, and new business development, among many others. ViroMed Co., Ltd. started as a spin-off company and has grown to become a publicly listed KOSDAQ company, with its market cap ranked 8th. ViroMed has assembled a diverse, yet technologically and conceptually linked pipeline of new and innovative therapeutics in areas such as cardiovascular, neurological diseases, and cancers. She was recently awarded 2016 National R&D Excellence Award from the Ministry of Science, ICT, and Future Planning of Korea.